Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on interventional oncology. Their primary mission is to develop and commercialize innovative therapies for the treatment of primary and metastatic liver cancers. The company's proprietary system, the Delcath Hepatic Delivery System (commercially available as CHEMOSTAT® in Europe and HEPZATO™ KIT in the U.S.), is designed to administer high-dose chemotherapy directly to the liver while controlling systemic exposure. This targeted approach aims to improve efficacy and reduce the side effects associated with traditional chemotherapy. Delcath is committed to advancing cancer care and addressing unmet medical needs for patients with liver-dominant cancers.
Serves as the central hub for strategic decision-making, corporate governance, investor relations, business development, and overall operational management for its global activities in the oncology sector.
Located in the Paramount Plaza building, a prominent Manhattan office skyscraper, offering access to a major business and financial hub. Internal features are modern corporate office facilities.
A dynamic and focused environment, driven by innovation in the oncology field. Emphasis on scientific rigor, patient outcomes, regulatory compliance, and commercialization efforts. Collaborative atmosphere typical of biotech/pharma companies striving to bring new treatments to market.
The New York City location provides strategic advantages, including proximity to financial markets, potential partners, leading medical institutions, and a diverse talent pool. It facilitates engagement with the investment community and key stakeholders in the healthcare industry.
Delcath Systems, Inc. supports global functions primarily focused on the development, regulatory approval, and commercialization of its liver-directed therapies. This includes managing clinical trials in multiple countries, engaging with regulatory bodies such as the FDA (U.S.) and European authorities, and establishing commercial infrastructure and partnerships for product distribution in approved markets. Their primary operational focus is currently in North America (with the U.S. launch of HEPZATO™ KIT) and Europe (with CHEMOSTAT®).
1633 Broadway, Suite 22C
New York
NY
United States
Address: Unit 27, Briarhill Business Park, Galway, Ireland
Serves as a key hub for managing and expanding Delcath's presence in the European market, engaging with European healthcare professionals and regulatory authorities, and supporting the distribution and use of their oncology products in the region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Delcath Systems' leadership includes:
Delcath Systems has been backed by several prominent investors over the years, including:
Delcath Systems has significantly strengthened its leadership team over the past 12 months with key appointments including a new Chief Operating Officer, Chief Financial Officer, and General Counsel. Additionally, the Interim CEO was formally appointed as President & CEO. These changes are pivotal as the company focuses on the U.S. commercial launch of HEPZATO™ KIT and ongoing operations.
Discover the tools Delcath Systems uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Delcath Systems, Inc. most likely utilizes the email format of the first initial followed by the last name @delcath.com. While variations can exist within organizations, this is a common and often primary format for corporate communications.
[first_initial][last]@delcath.com
Format
gdangelo@delcath.com
Example
85%
Success rate
Delcath Systems, Inc. Press Release • August 14, 2023
Delcath Systems announced FDA approval for its HEPZATO KIT (melphalan/Hepatic Delivery System) for adult patients with metastatic uveal melanoma (mUM) with unresectable liver metastases. This marks a significant milestone for the company and patients with this rare and aggressive cancer....more
Delcath Systems, Inc. Press Release • February 13, 2024
Delcath Systems announced the U.S. commercial launch of HEPZATO KIT for treating metastatic uveal melanoma (mUM). The company has initiated activities to make the therapy available to patients at trained treatment centers across the country....more
Delcath Systems, Inc. Press Release • March 19, 2024
Delcath Systems announced the appointment of Megan Po Rielly as General Counsel. Ms. Rielly brings over 20 years of legal experience in the life sciences industry and will be responsible for overseeing the company's legal affairs and strategy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Delcath Systems, are just a search away.